[68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients

  • João Carvalho | joao.andre.mendes.carvalho@gmail.com Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.
  • Pedro Nunes Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.
  • Edgar Tavares da Silva Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.
  • Rodolfo Silva Faculty of Medicine, Coimbra University, Coimbra; Department of Nuclear Medicine; Coimbra University Hospital Center, Coimbra, Portugal.
  • João Lima Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.
  • Vasco Quaresma Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.
  • Arnaldo Figueiredo Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra, Portugal.

Abstract

Objectives: Clinical approach of prostate cancer (PCa) biochemical recurrence (BCR) is an ever-changing topic. Prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11 PET-CTPSMA PET-CT) has shown good potential in this field. The aim is to evaluate PSMA PET-CT detection rate in PCa BCR and assess its impact on clinical outcome.
Material and methods: Out of 319 patients with PCa who underwent PSMA PET-CT between October 2015 and June 2019, 70 had developed BCR after treatment with curative intent. Two groups were created: one with BCR after surgery (RP group) (N: 48; 68.6%) and other with BCR after radiotherapy (RT group) (N: 22; 31.4%). Clinical, analytical, pathological and PSMA PET-CT results were evaluated.
Results: Initial age was different between groups (p = 0.008). RP patients were mainly at intermediate risk (85.1% vs 42.9%, p = 0.001) while RT patients were at low risk of recurrence (8.5% vs 47.6%, p = 0.001). In RP and RT groups, PSMA PETCT detected, respectively, pelvic relapse in 31.3% and 63.6%, and extrapelvic relapse in 18.8% and 31.8%. Salvage treatment was performed in 61.9% (n = 26) of RP patients and in 15% (n = 3) of RT patients, p < 0.001. Of RP patients submitted to salvage treatment, 59.1% achieved complete remission. Concerning these patients, local radiotherapy led to complete remission in 68.4% (n = 13). Of RT patients submitted to salvage treatment, two had complete remission and one had partial remission.Concerning detection rate, PSMA PET-CT was positive for pelvic relapse when pre-PET PSA ≥ 0.8 ng/mL (RP) or ≥ 2.3 ng/mL (RT) and for extrapelvic relapse when PSA ≥ 0.4 ng/mL (RP) or ≥ 3.5 ng/mL (RT), p > 0.05.
Conclusions: Biochemical persistence rate after salvage therapy was similar (30-40%). The cut-off PSA values for pelvic relapse detected on PSMA PET-CT were ≥ 0.8 ng/mL (RP) and ≥ 2.3 ng/mL (RT).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-86. DOI: https://doi.org/10.1002/ijc.29210

Freedland SJ, Humphreys EB, Mangold L, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostatespecific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765-71. DOI: https://doi.org/10.1200/JCO.2006.08.0572

Toussi A, Stewart-Merrill SB, Boorjian SA, et al. Standardizing the definition of biochemical recurrence after radical prostatectomy- What prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? J Urol. 2016;195:1754-9. DOI: https://doi.org/10.1016/j.juro.2015.12.075

Roach M, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol; Phys. 2006; 65:965-74. DOI: https://doi.org/10.1016/j.ijrobp.2006.04.029

Van den Broeck, van den Bergh R, Briers E, et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations Eur Urol Focus. 2020; 6:231-234. DOI: https://doi.org/10.1016/j.euf.2019.06.004

Eissa A, Elsherbiny A, Coelho RF, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018; 70:462-478. DOI: https://doi.org/10.23736/S0393-2249.18.03081-3

Albisinni S, Artigas C, Aoun F, et al. Clinical impact of 68 Gaprostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120:197-203. DOI: https://doi.org/10.1111/bju.13739

Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med. 2017;58:1972-6. DOI: https://doi.org/10.2967/jnumed.117.196683

Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44:1258-68

Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis Eur Urol 2016; 70:926-37.

Meredith G, Wong D, Yaxley J, et al. The use of 68 G a-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118:49-55. DOI: https://doi.org/10.1111/bju.13616

Mottet N, van den Bergh R, Briers E, et al. EAU - EANM -ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020.

Aboagye EO, Kraeber-Bodéré F. Highlights lecture EANM 2016: “Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine”. Eur J Nucl Med Mol Imaging. 2017; 44:1559-1574. DOI: https://doi.org/10.1007/s00259-017-3704-6

Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigenavid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020; 77:403-417. DOI: https://doi.org/10.1016/j.eururo.2019.01.049

Budaus L, Leyh-Bannurah SM, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016; 69:393-6. DOI: https://doi.org/10.1016/j.eururo.2015.06.010

Demirci E, Kabasakal L, Sahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019; 40:86-91. DOI: https://doi.org/10.1097/MNM.0000000000000942

Sanli Y, Kuyumcu S, Sanli O, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31:709-717. DOI: https://doi.org/10.1007/s12149-017-1207-y

Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive (68) Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016; 70:926-937. DOI: https://doi.org/10.1016/j.eururo.2016.06.021

Eder M, Neels O, Müller M, et al. Novel preclinical and radiopharmaceutical aspects of [(68)Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7:779-96. DOI: https://doi.org/10.3390/ph7070779

Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65:124-137. DOI: https://doi.org/10.1016/j.eururo.2013.09.046

Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid68Ga-PSMA Ligand PET/CT in 248 Patients with BiochemicalRecurrence After Radical Prostatectomy. J Nucl Med. 2015; 56:668-74. DOI: https://doi.org/10.2967/jnumed.115.154153

Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44:1258-68. DOI: https://doi.org/10.1007/s00259-017-3711-7

Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018; 74:179-90. DOI: https://doi.org/10.1016/j.eururo.2018.03.030

Murphy DG, Sweeney CJ, Tombal B.Gotta catch ‘em al,” or do we? Pokemet approach to metastatic prostate cancer Eur Urol. 2017; 72:1-3. DOI: https://doi.org/10.1016/j.eururo.2017.02.036

Published
2021-03-18
Info
Issue
Section
Original Papers - Oncology
Keywords:
Biochemical recurrence, PSMA PET-CT, Salvage treatment, Prostate cancer
Statistics
  • Abstract views: 128

  • PDF: 76
How to Cite
Carvalho, J., Nunes, P., da Silva, E. T., Silva, R., Lima, J., Quaresma, V., & Figueiredo, A. (2021). [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Archivio Italiano Di Urologia E Andrologia, 93(1), 21-25. https://doi.org/10.4081/aiua.2021.1.21